Genedata, a leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, today announced that Asubio Pharma, a wholly-owned subsidiary of Daiichi Sankyo Co., Ltd, is using the Genedata Expressionist® system to support their compound profiling and biomarker discovery process.
"We were looking for a bioinformatics solution to manage a huge volume of DNA array data generated internally at Asubio as well as to integrate additional external molecular profiling data,” said Dr. Michinori Kadokura, Associate Senior Researcher at Asubio Pharma. “After a thorough market evaluation, we chose Genedata Expressionist because the system allows us to easily manage large volumes of data in a high-throughput manner and gives bioinformaticians across the company centralized access for data sharing. Furthermore, we are interested in cross-omics analysis which is uniquely supported by Expressionist.”
The Expressionist module Analyst is being used at Asubio Pharma as an ultra high-throughput framework for integrated statistical analysis for biomarker discovery. Analyst features top-tier statistical algorithms, intuitive visualizers and unique technology to integratively analyze data from different omics technologies. Powered by a flexible workflow system and designed to analyze over one billion data points in real-time, Analyst can accommodate both in-house and public domain algorithms for statistical analysis.
“We are very excited to be working with Asubio Pharma, a highly innovative Japanese pharmaceutical company,” commented Dr. Othmar Pfannes, CEO of Genedata. “The Japanese life science market plays an important role in Genedata’s growth strategy. Led by the Genedata Tokyo office, we have been able to rapidly provide innovative solutions to a large number of pharmaceutical and biotechnology companies in Asia.”
About Asubio Pharma
Asubio Pharma (asubio.co.jp) is a wholly owned subsidiary of Daiichi Sankyo Co., Ltd, dedicated to healing illness and alleviating the pain of patients all over the world by providing superior pharmaceuticals and medical services, based on advanced scientific research and in strict accordance with ethics and rational economics. We focus on new drug discovery through in-house efforts while taking full advantage of the global development capabilities and technology platforms of the Daiichi Sankyo Group and continue our commitment to enhance the quality of life around the world by creating safe and effective drugs that fill unmet therapeutic needs. Achievements to date include the in-house development of Sunrythm®, HANP® and three other new drugs on the market.
Genedata (genedata.com) develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata’s solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high throughput technologies. Solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.